Avexitide

What is Avexitide?

Avexitide is the developmental name for exendin-(9-39), the C-terminal 31-amino-acid fragment of the 39-amino-acid Gila monster venom peptide exendin-4. Pharmacologically it is the inverse of every other GLP-1 directory entry on this site: where semaglutide, tirzepatide, liraglutide, and exenatide are GLP-1 receptor *agonists* that enhance insulin secretion, avexitide is a GLP-1 receptor *antagonist* that competitively blocks GLP-1 receptor activation and reduces GLP-1-driven insulin secretion. The N-terminal His-Gly that defines exendin-4's agonist activity is what avexitide lacks. Originally developed by Eiger BioPharmaceuticals as a treatment for two narrow but serious hypoglycemic disorders — post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (CHI) — the asset was acquired by Amylyx in July 2024 out of Eiger's bankruptcy and has now cleared Phase 3 for the PBH indication. On 18 August 2026 Amylyx reported that the Phase 3 LUCIDITY trial met its FDA-agreed primary endpoint with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003), the first Phase 3 success for a GLP-1 receptor antagonist mechanism in any indication. Two FDA Breakthrough Therapy Designations (PBH in 2019, congenital hyperinsulinism in 2021), Orphan Drug Designation for hyperinsulinemic hypoglycemia, and Rare Pediatric Disease Designation in CHI support an expedited path; an NDA is planned by the end of 2026 with commercial launch anticipated in 2027 if approved.

What Avexitide Is Investigated For

Avexitide has two clinical centers of gravity, both serious hypoglycemic disorders driven by inappropriate insulin secretion. The evidence in post-bariatric hypoglycemia is now Phase 3 grade. The groundwork was a Phase 1 single-ascending-dose study (Craig et al. 2018) and two Phase 2 trials — a multiple-ascending-dose study (Tan et al. 2020) and the randomized placebo-controlled crossover PREVENT trial (Craig et al., J Clin Endocrinol Metab 2021; NCT03373435, n=18), which raised the postprandial glucose nadir by 21% on 30 mg twice daily and 26% on 60 mg once daily while cutting the number of participants needing rescue by half or more. An investigator-initiated Phase 2b (NCT04652479) then tested 45 mg twice daily and 90 mg once daily and selected the once-daily regimen. The pivotal trial is LUCIDITY (NCT06747468), Amylyx's Phase 3: 78 adults with PBH across 21 US sites, randomized 3:2 to avexitide 90 mg subcutaneously once daily or placebo for 16 weeks, followed by a 32-week open-label extension. On 18 August 2026 Amylyx reported that LUCIDITY met its FDA-agreed primary endpoint with a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003) and met all secondary endpoints across self-monitored Level 2 events, CGM-measured Level 2 events, and independently adjudicated Level 3 events. Notably, body weight did not change in either arm over the double-blind period — useful confirmation that blocking the GLP-1 receptor at this dose does not act as a reverse weight-loss drug. The second indication is congenital hyperinsulinism, where Stefanovski et al. 2022 (Diabetes Care) and Ng et al. 2018 (a population pharmacokinetic and dose-selection study) demonstrated that exendin-(9-39) raises glucose and reduces inappropriate insulin secretion in children; three Phase 2 studies in 39 pediatric patients are complete, but no trial is currently enrolling and Amylyx has said it is still working out a development path with the CHI community. Beyond therapeutics, avexitide remains a standard research probe — infusing it to block GLP-1 signaling lets investigators quantify how much of an observed insulin response depends on the GLP-1 axis, as in a 2026 study in totally pancreatectomized individuals. The honest caveats: avexitide is still not approved for any indication, the LUCIDITY results exist only as a company press release with no peer-reviewed publication and no disclosed secondary-endpoint magnitudes, and safety data beyond the 16-week double-blind period plus open-label extension remain limited for what would be lifelong therapy.

History & Discovery

Exendin-(9-39) entered the scientific literature in the late 1980s and 1990s as a research tool — once exendin-4 was identified as a GLP-1 receptor agonist, truncating its N-terminus produced a competitive antagonist that became the standard pharmacological probe for blocking GLP-1 signaling. Hundreds of preclinical and translational papers have used exendin-(9-39) to dissect how much of a given physiological or pharmacological insulin response depends on the GLP-1 axis. The therapeutic development arc began later, driven by a recognized clinical need: as Roux-en-Y gastric bypass surgery became increasingly common in the 2000s and 2010s, a meaningful subset of post-bariatric patients developed severe symptomatic late-postprandial hypoglycemia that did not respond to dietary management. Older estimates put this at 0.2–5% of RYGB recipients depending on definition, but a 2026 US prevalence review from Craig, Ramanujan, and McLaughlin (Surg Obes Relat Dis) revised the picture substantially upward — roughly 30% of RYGB and 10% of sleeve gastrectomy patients develop hypoglycemia, with about 12% of RYGB and 5% of SG patients requiring medical attention, amounting to an estimated 160,000 US patients needing medical management. Tracy McLaughlin's group at Stanford was central to establishing that the syndrome is driven primarily by exaggerated GLP-1 release and that GLP-1 receptor blockade reverses it — work anchored by the Craig et al. 2017 Diabetologia paper and carried into the therapeutic development program. Eiger BioPharmaceuticals took avexitide through Phase 1 (Craig et al. 2018) and Phase 2 in PBH — the multiple-ascending-dose study (Tan et al. 2020) and the randomized placebo-controlled crossover PREVENT trial (Craig et al., J Clin Endocrinol Metab 2021, NCT03373435, n=18) — with parallel CHI development (Stefanovski et al. 2022; Ng et al. 2018). FDA granted Breakthrough Therapy Designation for PBH on 17 June 2019 and a second Breakthrough Therapy Designation for congenital hyperinsulinism on 5 August 2021, the latter supported by three completed Phase 2 studies in 39 neonates, children, and adolescents. Orphan Drug Designation for hyperinsulinemic hypoglycemia and Rare Pediatric Disease Designation in CHI followed, alongside an EMA orphan designation for congenital hyperinsulinism. In 2024 Eiger filed for Chapter 11 bankruptcy following an unrelated business setback, and its avexitide program went to auction. Amylyx Pharmaceuticals prevailed on 17 June 2024, signed the asset purchase agreement on 21 June, received bankruptcy court approval on 26 June, and closed on 9 July 2024 for $35.1 million plus cure costs and assumed liabilities — including a 3% royalty on future PBH sales owed to certain academic institutions. Amylyx designed and ran the pivotal Phase 3 trial, LUCIDITY (NCT06747468), which began enrolling on 29 April 2025 and randomized 78 adults with PBH across 21 US sites 3:2 to avexitide 90 mg subcutaneously once daily or placebo for 16 weeks, with a 32-week open-label extension. Topline results on 18 August 2026 showed a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003), with all secondary endpoints met and no serious adverse events attributed to treatment. Amylyx opened a US Expanded Access Program in May 2026 and plans to submit an NDA by the end of 2026, with commercial launch anticipated in 2027 if approved. That would make avexitide the first FDA-approved therapy for post-bariatric hypoglycemia and the first approved drug of any kind working through GLP-1 receptor antagonism. The program has a designated successor. On 8 January 2026 Amylyx nominated AMX0318, a novel long-acting GLP-1 receptor antagonist peptide discovered through a research collaboration with the Danish peptide-discovery company Gubra A/S, as a development candidate — triggering a $4 million milestone payment to Gubra, with more than $50 million in total success-based development and commercialization milestones plus mid-single-digit royalties on worldwide net sales. Amylyx reported that AMX0318 completed preclinical stability, solubility, potency, pharmacokinetic, and tolerability characterization with a profile 'consistent with a long-acting peptide,' though no numeric data have been released and the company has not specified a dosing interval — descriptions of AMX0318 as a 'weekly' product are inference, not disclosure. IND-enabling studies were underway as of mid-2026 with an IND filing targeted for 2027, aimed at PBH and other rare diseases involving excessive endogenous GLP-1 signaling. Taken together, the asset is the proof case for a broader pharmacological logic: GLP-1 signaling matters bidirectionally — agonism for hyperglycemia and obesity, antagonism for hyperinsulinemic hypoglycemia.

How It Works

Avexitide blocks the GLP-1 receptor. GLP-1 is a gut hormone that tells the pancreas to release insulin after meals — useful in normal physiology, but harmful when it goes into overdrive after gastric bypass or in congenital hyperinsulinism. By blocking the receptor, avexitide prevents the inappropriate insulin spike and stops the dangerous low blood sugar that follows.

Avexitide is the C-terminal fragment (residues 9–39) of exendin-4, the full 39-amino-acid GLP-1 receptor agonist from Heloderma suspectum (Gila monster) venom. The first eight N-terminal residues of exendin-4 — particularly His-Gly at positions 1–2 — are required for receptor activation; the remaining C-terminal portion provides high-affinity receptor binding without activation. Truncating the N-terminus produces a competitive antagonist that binds the GLP-1 receptor with affinity comparable to native GLP-1 but does not activate downstream Gs/cAMP/PKA signaling. The net effect is competitive blockade of endogenous GLP-1 action, preventing GLP-1-driven amplification of glucose-stimulated insulin secretion from pancreatic beta cells. In post-bariatric hypoglycemia, the underlying pathophysiology is exaggerated postprandial GLP-1 release from L-cells (driven by the rapid delivery of nutrients to the distal small bowel after Roux-en-Y gastric bypass), producing hyperinsulinemia disproportionate to the glycemic load and reactive hypoglycemia within 1–3 hours of eating — a condition Patti 2026 SOARD (PMID 42469084) recently characterized as an under-recognized clinical challenge in modern bariatric practice, warranting broader clinical awareness and pre-operative counseling on risk factors. Avexitide blocks the amplification step, restoring more physiologic insulin secretion and preventing the hypoglycemic nadir. In congenital hyperinsulinism, the underlying defect involves dysregulated beta-cell insulin secretion (most commonly via mutations in KATP channel components ABCC8 or KCNJ11); avexitide reduces the GLP-1 contribution to that dysregulated secretion. The dosing regimen deserves a note because it evolved during development. Early Phase 2 work used twice- and three-times-daily subcutaneous administration on the assumption that meal-timed dosing was required to cover each postprandial GLP-1 surge. Population pharmacokinetic and pharmacodynamic analyses presented at ENDO 2025 overturned that assumption: avexitide 90 mg once daily maintains plasma concentrations above the GLP-1 receptor IC50 across a full 24-hour period, producing consistent receptor inhibition from morning through midnight and between doses. The Phase 3 LUCIDITY trial accordingly used a single 90 mg subcutaneous dose each day, taken at least 60 minutes before breakfast, and the Phase 2b 90 mg once-daily arm had already produced a 64% least-squares mean reduction in Level 2 and Level 3 hypoglycemic events (p=0.0031) with more than half of participants experiencing no events during treatment.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Avexitide:

• 01Peer-reviewed publication of LUCIDITY — the Phase 3 result exists so far only as an Amylyx press release. The primary endpoint magnitude and p-value are disclosed, but individual secondary-endpoint values, discontinuation counts, and the full adverse-event table are not, and no manuscript has appeared.
• 02Long-term safety beyond Phase 3 trial duration — the chronic nature of PBH and CHI means decades of avexitide use is expected, but available safety data extends only through the 16-week double-blind period and the 32-week open-label extension.
• 03Pediatric long-term use in CHI — children with CHI may use avexitide for decades; longitudinal growth, development, and cardiovascular outcomes are not yet characterized.
• 04Response heterogeneity in PBH — some patients respond robustly to avexitide while others have partial response; mechanistic predictors of response have not been fully characterized.
• 05Optimal positioning vs. existing PBH therapies — how avexitide should be sequenced with dietary modification, acarbose, diazoxide, somatostatin analogs, and (rarely) partial pancreatectomy is not yet standardized.
• 06Pregnancy and lactation safety — entirely uncharacterized; affected pregnant patients with severe PBH face particular clinical challenges.
• 07Once-daily or extended-release formulations — current twice/thrice daily SC dosing is burdensome; whether a longer-acting formulation could achieve adequate meal-coverage is an active development question.
• 08Use in late-dumping-syndrome-equivalent hypoglycemia after other bariatric procedures (vertical sleeve gastrectomy, biliopancreatic diversion) — most evidence is in post-RYGB; extending to other procedures has limited dedicated data. Cook 2026 Mol Metab (PMID 42270043) further complicates this by showing that dysregulated glucagon signaling contributes to hypoglycemia in a VSG mouse model, suggesting VSG-associated hypoglycemia has distinct pathophysiology that avexitide's GLP-1-antagonism-only mechanism may not fully address.

Forms & Administration

Subcutaneous injection, 90 mg once daily, taken at least 60 minutes before breakfast — the regimen used in the Phase 3 LUCIDITY trial. Self-administration after patient or caregiver training has been used throughout the trial program. Avexitide is not commercially available; Amylyx opened a US Expanded Access Program in May 2026 for adults with PBH following Roux-en-Y gastric bypass, and clinical trial or expanded-access enrollment remain the only legitimate routes of supply pending FDA review.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Avexitide is not FDA-approved for any indication. Phase 3 succeeded in August 2026 and an NDA is planned by the end of 2026, but the drug remains investigational pending FDA review. Treatment of PBH or CHI requires specialty endocrinology and bariatric medicine care. The information here is for educational reference, not treatment direction.

Timeline of Effects

Common Questions

Who Avexitide Is NOT For

Drug & Supplement Interactions

Avexitide's most clinically important interaction is mechanistic rather than pharmacokinetic: concurrent use with GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide, mazdutide, retatrutide) is mechanistically contradictory and contraindicated. These drug classes have opposite effects on the GLP-1 receptor; combining them would either neutralize both or produce unpredictable receptor pharmacology. With DPP-4 inhibitors (sitagliptin, linagliptin, etc.) — which prolong endogenous GLP-1 and GIP activity by inhibiting their degradation — the combination is similarly contraindicated. The DPP-4 inhibitor mechanism depends on amplifying endogenous incretin signaling that avexitide is designed to block. With insulin secretagogues (sulfonylureas: glipizide, glyburide; meglitinides: repaglinide, nateglinide) — these drugs stimulate insulin secretion independent of GLP-1 and are not blocked by avexitide. Patients on these agents who develop appropriate hypoglycemia from the secretagogue itself need adjustment of the secretagogue rather than addition of avexitide. Diazoxide is a different class (KATP channel opener that reduces insulin secretion) and has been used off-label for severe refractory PBH and as standard CHI therapy. Avexitide and diazoxide have distinct mechanisms and may potentially be combined for refractory disease — clinical trial protocols have varied. Octreotide (somatostatin analog) similarly has a different mechanism. Acarbose (alpha-glucosidase inhibitor) reduces postprandial carbohydrate absorption and is mechanistically complementary. Given avexitide's narrow approved-population scope, drug interaction concerns center primarily on the GLP-1 axis. Patients on any chronic medication should disclose all therapy to their managing endocrinologist before initiating avexitide.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions